Activation of AURKA contributes to TKI resistance in EGFR-mutant non-small lung cancer

被引：0
|
作者：
Lee, Meng-Hsuan [1 ]
Hong, Shiao-Ya [2 ]
Kao, Yu-Rung [2 ]
Wu, Cheng-Wen [1 ]
机构：
[1] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei, Taiwan
[2] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.SABCS18-4756
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4756
引用
收藏
页数：2
相关论文
共 50 条
  • [1] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Otsuka, Kyoko
    Hata, Akito
    Takeshita, Jumpei
    Okuda, Chiyuki
    Kaji, Reiko
    Masago, Katsuhiro
    Fujita, Shiro
    Katakami, Nobuyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 835 - 841
  • [2] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Kyoko Otsuka
    Akito Hata
    Jumpei Takeshita
    Chiyuki Okuda
    Reiko Kaji
    Katsuhiro Masago
    Shiro Fujita
    Nobuyuki Katakami
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 835 - 841
  • [3] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Ortiz-Cuaran, Sandra
    Ricciuti, Biagio
    Mezquita, Laura
    Cardona, Andres Felipe
    Recondo, Gonzalo
    CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591
  • [4] Beyond EGFR TKI in EGFR-mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome
    Remon, J.
    Moran, T.
    Reguart, N.
    Majem, M.
    Carcereny, E.
    Lianes, P.
    CANCER TREATMENT REVIEWS, 2014, 40 (06) : 723 - 729
  • [5] Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
    Ding, Jianghua
    Ding, Xingjing
    Zeng, Jiao
    Liu, Xiaoqun
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [6] Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer
    Zhang, Chen
    Cao, Honggang
    Cui, Yanan
    Jin, Shidai
    Gao, Wen
    Huang, Chenjun
    Guo, Renhua
    THORACIC CANCER, 2021, 12 (19) : 2574 - 2584
  • [7] PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
    Sos, Martin L.
    Koker, Miriam
    Weir, Barbara A.
    Heynck, Stefanie
    Rabinovsky, Rosalia
    Zander, Thomas
    Seeger, Jens M.
    Weiss, Jonathan
    Fischer, Florian
    Frommolt, Peter
    Michel, Kathrin
    Peifer, Martin
    Mermel, Craig
    Girard, Luc
    Peyton, Michael
    Gazdar, Adi F.
    Minna, John D.
    Garraway, Levi A.
    Kashkar, Hamid
    Pao, William
    Meyerson, Matthew
    Thomas, Roman K.
    CANCER RESEARCH, 2009, 69 (08) : 3256 - 3261
  • [8] Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
    Digumarthy, Subba R.
    Mendoza, Dexter P.
    Padole, Atul
    Chen, Tianqi
    Peterson, P. Gabriel
    Piotrowska, Zofia
    Sequist, Lecia, V
    CANCERS, 2019, 11 (09)
  • [9] EGFR-TYROSINE KINASE INHIBITOR (TKI) RECHALLENGE WITH BEVACIZUMAB IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Otsuka, K.
    Hata, A.
    Kato, R.
    Takeshita, J.
    Okuda, C.
    Kaji, R.
    Masago, K.
    Fujita, S.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2014, 25
  • [10] MERTK activation drives osimertinib resistance in EGFR-mutant non small cell lung cancer
    Yan, Dan
    Huelse, Justus M.
    Kireev, Dmitri
    Tan, Zikang
    Chen, Luxiao
    Goyal, Subir
    Wang, Xiaodong
    Frye, Stephen, V
    Behera, Madhusmita
    Schneider, Frank
    Ramalingam, Suresh S.
    Owonikoko, Taofeek
    Earp, H. Shelton
    DeRyckere, Deborah
    Graham, Douglas K.
    JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (15):
12345